

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF THE SENATE

05 FEB -8 PM 3:

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name			
Organization		Aventis Pharmaceuticals (formerly known as Aventis Pharma)	
2. Address <input type="checkbox"/> Check if different than previously reported			
801 Pennsylvania Avenue NW		Suite 725	
City	Washington	State	DC
Zip Code	20004	Country	US
3. Principal place of business (if different than line 2)			
City	State	Zip Code	Country
4a. Contact Name		b. Telephone number	c. E-mail
Prefix	Full Name		
Ms.	Ann Taylor	(202) 898-3183	ann.taylor@sanofi-aventis.com
7. Client Name <input checked="" type="checkbox"/> Self			5. Senate ID #
Aventis Pharmaceuticals (formerly known as Aventis Pharma)			56838-1
			6. House ID #
			351860

TYPE OF REPORT 8. Year 2004 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇨ Termination Date 12/31/04 11. No Lobbying Act

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13	
12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000 <input type="checkbox"/>	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input type="checkbox"/> ⇨ \$ <u> </u>	\$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>1,344,000</u>
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate exp accounting method. See instructions for description of opt
	<input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions
	<input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(Internal Revenue Code
	<input type="checkbox"/> Method C. Reporting amounts under section 162(e) of Revenue Code

Form C

Ann Taylor 2/4/05

Printed Name and Title Ann Taylor, Director, Health Policy and Pharmaceutical Programs

Registrant Name Aventis Pharmaceuticals (formerly known Client Name Aventis Pharmaceuticals (formerly known

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code and provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM - Medicare/Medicaid (one per page)

16. Specific lobbying issues *Add page to continue specific issues description for this issue* 

Medicare Prescription Drug, Improvement and Modernization Act of 2003 (MMA)
All provisions.

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives
U.S. Senate

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for this issue*

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Eddie	Evans		
Ann	Taylor		
Richard	Hodge		

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharmaceuticals is part of Aventis SA. Aventis Pharmaceuticals' interest in this issue is to ensure that essential pharmaceutical benefit coverage is available to the Medicare population through implementation of this public

Registrant Name Aventis Pharmaceuticals (formerly known Client Name Aventis Pharmaceuticals (formerly known

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code and provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM - Medicare/Medicaid (one per page)

16. Specific lobbying issues *Add page to continue specific issues description for this issue*

Discussions with the Centers for Medicaid and Medicare Services (CMS) on implementation of the MMA.

17. House(s) of Congress and Federal agencies contacted Check if None

Centers for Medicaid and Medicare Services, Department of Health and Human Services.

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for*

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Judy	Cook		
Eddie	Evans		
Ann	Taylor		
Richard	Hodge		

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharmaceuticals is part of Aventis SA. Aventis Pharmaceuticals' interest in this issue is to ensure that essential pharmaceutical benefit coverage is available to the Medicare population through implementation of this public

Registrant Name Aventis Pharmaceuticals (formerly known Client Name Aventis Pharmaceuticals (formerly known

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code BUD - Budget/Appropriations (one per page)

16. Specific lobbying issues *Add page to continue specific issues description for this issue*

H.R. 2673 "Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act, 2004"
S. 1427 "Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act, 2004"

All provisions relating to reimportation.

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for*

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Ann	Taylor		
Richard	Hodge		

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharmaceuticals is part of Aventis SA. Aventis Pharmaceuticals' interest in this issue is to ensure that the safe pharmaceuticals are preserved for all Americans.

Registrant Name Aventis Pharmaceuticals (formerly known Client Name Aventis Pharmaceuticals (formerly known

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant was engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code and provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR - Health Issues (one per page)

16. Specific lobbying issues *Add page to continue specific issues description for this issue*

Discussion of draft diabetes-related legislation.

17. House(s) of Congress and Federal agencies contacted Check if None

House

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for this issue*

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Judy	Cook		

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Aventis SA is a stock corporation under French Commercial law, headquartered in Strasbourg, France. Aventis Pharmaceuticals is part of Aventis SA. Aventis Pharmaceuticals' interest in this issue is to ensure that essential pharmaceutical benefit coverage is available to the Medicare population.

